North America Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Country and Growth Forecast, 2022

List of Tables

The North America Gastroesophageal Reflux Disease Therapeutics Market would witness market growth of 1.5% CAGR during the forecast period (2022-2028).

A burning sensation behind the breastbone is a symptom of gastroesophageal reflux disease (GERD), characterized by the reflux of stomach contents into the mouth via the esophagus. The lower oesophageal sphincter and the digestive tract's suppleness are impacted by gastroesophageal reflux disease (GERD), a common digestive disorder. Dietary changes, lifestyle changes, and excessive consumption of fatty foods, coffee, alcohol, citrus fruits, and pepper bring on gastroesophageal reflux disease.

Gastroesophageal reflux disease, brought on by excessive acid production and finally results in ulcers, rips the stomach's lining apart. Regurgitation and dysphagia are two additional symptoms of gastroesophageal reflux disease. Common symptoms of abnormal reflux include coughing, sore throat, otitis media, chest pain, enamel erosion, or other dental symptoms.

Inadequate esophageal clearance of refluxate may increase the amount of time that refluxate is in touch with the distal esophageal mucosa, which increases the likelihood that symptoms will develop or that the epithelium may be harmed. The key events that clear the refluxate are primary (swallow-induced) and secondary (distension-induced) peristalses. Around 30% of GERD patients have esophageal motility abnormalities, with inefficient esophageal motility being the most common change.

The World Health Organization's (WHO) burden of disease studies places alcohol intake as the second-highest etiologic risk factor in high-income nations like Canada. According to statistics from 2002, the projected yearly cost of health care directly associated with alcohol use in Canada was $3.3 billion, while the overall direct and indirect cost was $14.6 billion. The significant illness burden caused by alcohol in Canada is anticipated to rise due to many important factors. In addition, young individuals are more likely to engage in high-risk drinking. Around 32% of Canadians had issues the previous year due to other people's drinking, and almost one in five drinks more than the limits suggested for low-risk drinking. The growing population who consumes alcohol will increase the cases of gastroesophageal reflux diseases and surge the market growth in the region.

The US market dominated the North America Gastroesophageal Reflux Disease Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,501.1 Million by 2028. The Canada market is poised to grow at a CAGR of 3.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 2.9% during (2022 - 2028).

Based on Type, the market is segmented into Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).

Scope of the Study

Market Segments covered in the Report:

By Type

Antacids
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Pro-kinetic Agents

By Country

US
Canada
Mexico
Rest of North America

Companies Profiled

AstraZeneca PLC
Eisai Co., Ltd.
GlaxoSmithKline PLC
Takeda Pharmaceutical Company Limited
Ironwood Pharmaceuticals, Inc.
Johnson & Johnson
Medigus Ltd.
Sebela Pharmaceuticals
Phathom Pharmaceuticals, Inc.
Camber Pharmaceuticals, Inc. (Hetero Labs Limited)

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 North America Gastroesophageal Reflux Disease Therapeutics Market, by Type
- 1.4.2 North America Gastroesophageal Reflux Disease Therapeutics Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. North America Gastroesophageal Reflux Disease Therapeutics Market by Type

3.1 North America Antacids Market by Country
3.2 North America Proton Pump Inhibitors (PPIs) Market by Country
3.3 North America H2 Receptor Blockers Market by Country
3.4 North America Pro-kinetic Agents Market by Country

Chapter 4. North America Gastroesophageal Reflux Disease Therapeutics Market by Country

4.1 US Gastroesophageal Reflux Disease Therapeutics Market
- 4.1.1 US Gastroesophageal Reflux Disease Therapeutics Market by Type
4.2 Canada Gastroesophageal Reflux Disease Therapeutics Market
- 4.2.1 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type
4.3 Mexico Gastroesophageal Reflux Disease Therapeutics Market
- 4.3.1 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type
4.4 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market
- 4.4.1 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type

Chapter 5. Company Profiles

5.1 Takeda Pharmaceutical Company Limited
- 5.1.1 Company Overview
- 5.1.2 Financial Analysis
- 5.1.3 Regional Analysis
- 5.1.4 Research & Development Expense
5.2 AstraZeneca PLC
- 5.2.1 Company Overview
- 5.2.2 Financial Analysis
- 5.2.3 Regional Analysis
- 5.2.4 Research & Development Expenses
5.3 GlaxoSmithKline PLC (GSK)
- 5.3.1 Company Overview
- 5.3.2 Financial Analysis
- 5.3.3 Segmental and Regional Analysis
- 5.3.4 Research & Development Expense
5.4 Johnson & Johnson
- 5.4.1 Company Overview
- 5.4.2 Financial Analysis
- 5.4.3 Segmental &Regional Analysis
- 5.4.4 Research & Development Expenses
5.5 Ironwood Pharmaceuticals, Inc.
- 5.5.1 Company Overview
- 5.5.2 Financial Analysis
- 5.5.3 Regional Analysis
- 5.5.4 Research & Development Expenses
5.6 Eisai Co., Ltd.
- 5.6.1 Company Overview
- 5.6.2 Financial Analysis
- 5.6.3 Segmental and Regional Analysis
- 5.6.4 Research & Development Expenses
5.7 Medigus Ltd.
- 5.7.1 Company Overview
- 5.7.2 Financial Analysis
- 5.7.3 Segmental and Regional Analysis
- 5.7.4 Research & Development Expenses
5.8 Sebela Pharmaceuticals
- 5.8.1 Company Overview
- 5.8.2 Recent strategies and developments:
  - 5.8.2.1 Partnerships, Collaborations, and Agreements:
5.9 Phathom Pharmaceuticals, Inc.
- 5.9.1 Company Overview
- 5.9.2 Research & Development Expenses
- 5.9.3 Recent strategies and developments:
  - 5.9.3.1 Partnerships, Collaborations, and Agreements:
5.10. Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- 5.10.1 Company Overview
- 5.10.2 Recent strategies and developments:
  - 5.10.2.1 Product Launches and Product Expansions:

LIST OF TABLES

TABLE 1 North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 2 North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 3 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 4 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 5 North America Antacids Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Antacids Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
TABLE 9 North America H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
TABLE 10 North America H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
TABLE 12 North America Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
TABLE 13 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 15 US Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 16 US Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 17 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 18 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 19 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 20 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 21 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 22 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 23 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 24 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 25 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 26 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 27 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 28 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 29 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 30 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 31 Key Information - Takeda Pharmaceutical Company Limited
TABLE 32 KEY INFORMATION - AstraZeneca PLC
TABLE 33 Key Information - GlaxoSmithKline PLC
TABLE 34 Key information -Johnson & Johnson
TABLE 35 Key Information - Ironwood Pharmaceuticals, Inc.
TABLE 36 Key Information - Eisai Co., Ltd.
TABLE 37 Key Information - Medigus Ltd.
TABLE 38 Key Information - Sebela Pharmaceuticals
TABLE 39 Key Information - Phathom Pharmaceuticals, Inc.
TABLE 40 Key Information - Camber Pharmaceuticals, Inc.

List of Figures

FIG 1 Methodology for the research

North America Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Country and Growth Forecast, 2022 - 2028

Description

Table of Contents